ATA168099A - Pharmazeutische zusammensetzung enthaltend ein antigen - Google Patents

Pharmazeutische zusammensetzung enthaltend ein antigen

Info

Publication number
ATA168099A
ATA168099A AT0168099A AT168099A ATA168099A AT A168099 A ATA168099 A AT A168099A AT 0168099 A AT0168099 A AT 0168099A AT 168099 A AT168099 A AT 168099A AT A168099 A ATA168099 A AT A168099A
Authority
AT
Austria
Prior art keywords
antig
pharmaceutical composition
composition containing
pharmaceutical
composition
Prior art date
Application number
AT0168099A
Other languages
English (en)
Other versions
AT408721B (de
Inventor
Julia-Kristina Mag Fleitmann
Frank Dr Mattner
Michael Dr Buschle
Jack Dr Melling
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to AT0168099A priority Critical patent/AT408721B/de
Priority to PE2000001035A priority patent/PE20010704A1/es
Priority to EP10179386A priority patent/EP2269641A3/de
Priority to DE60029115T priority patent/DE60029115T2/de
Priority to AU79121/00A priority patent/AU7912100A/en
Priority to EP10179390A priority patent/EP2269642A3/de
Priority to AT00969387T priority patent/ATE331529T1/de
Priority to EP06101092A priority patent/EP1745798A3/de
Priority to PCT/EP2000/009657 priority patent/WO2001024822A2/en
Priority to ARP000105196A priority patent/AR025937A1/es
Priority to EP10179382A priority patent/EP2269640A3/de
Priority to EP10179393A priority patent/EP2269643A3/de
Priority to EP00969387A priority patent/EP1218031B1/de
Publication of ATA168099A publication Critical patent/ATA168099A/de
Application granted granted Critical
Publication of AT408721B publication Critical patent/AT408721B/de
Priority to US10/114,823 priority patent/US20030099663A1/en
Priority to US11/082,595 priority patent/US20050163797A1/en
Priority to US12/248,744 priority patent/US20090130135A1/en
Priority to US12/248,397 priority patent/US20090104217A1/en
Priority to US13/110,454 priority patent/US8277815B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT0168099A 1999-10-01 1999-10-01 Pharmazeutische zusammensetzung enthaltend ein antigen AT408721B (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AT0168099A AT408721B (de) 1999-10-01 1999-10-01 Pharmazeutische zusammensetzung enthaltend ein antigen
PE2000001035A PE20010704A1 (es) 1999-10-01 2000-09-29 Composicion farmaceutica que comprende un antigeno
EP10179393A EP2269643A3 (de) 1999-10-01 2000-10-02 Hcv Vakzine-Zusammensetzungen
AU79121/00A AU7912100A (en) 1999-10-01 2000-10-02 Pharmaceutical composition comprising an antigen
EP10179390A EP2269642A3 (de) 1999-10-01 2000-10-02 Hcv Vakzine-Zusammensetzungen
AT00969387T ATE331529T1 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung
EP06101092A EP1745798A3 (de) 1999-10-01 2000-10-02 Hcv vakzine-zusammensetzungen
PCT/EP2000/009657 WO2001024822A2 (en) 1999-10-01 2000-10-02 Pharmaceutical composition comprising an antigen
EP10179386A EP2269641A3 (de) 1999-10-01 2000-10-02 Hcv Vakzine-Zusammensetzungen
EP10179382A EP2269640A3 (de) 1999-10-01 2000-10-02 Hcv Vakzine-Zusammensetzungen
DE60029115T DE60029115T2 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung
EP00969387A EP1218031B1 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung
ARP000105196A AR025937A1 (es) 1999-10-01 2000-10-02 Composicion farmaceutica que comprende un antigeno, un inmunoestimulante y un adyuvante policationico.
US10/114,823 US20030099663A1 (en) 1999-10-01 2002-04-01 Pharmaceutical composition comprising an antigen
US11/082,595 US20050163797A1 (en) 1999-10-01 2005-03-17 Pharmaceutical composition comprising an antigen
US12/248,744 US20090130135A1 (en) 1999-10-01 2008-10-09 Hcv vaccines
US12/248,397 US20090104217A1 (en) 1999-10-01 2008-10-09 Pharmaceutical Composition Comprising An Antigen
US13/110,454 US8277815B2 (en) 1999-10-01 2011-05-18 Pharmaceutical composition comprising an antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0168099A AT408721B (de) 1999-10-01 1999-10-01 Pharmazeutische zusammensetzung enthaltend ein antigen

Publications (2)

Publication Number Publication Date
ATA168099A true ATA168099A (de) 2001-07-15
AT408721B AT408721B (de) 2002-02-25

Family

ID=3518675

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0168099A AT408721B (de) 1999-10-01 1999-10-01 Pharmazeutische zusammensetzung enthaltend ein antigen
AT00969387T ATE331529T1 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00969387T ATE331529T1 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung

Country Status (8)

Country Link
US (4) US20030099663A1 (de)
EP (6) EP1745798A3 (de)
AR (1) AR025937A1 (de)
AT (2) AT408721B (de)
AU (1) AU7912100A (de)
DE (1) DE60029115T2 (de)
PE (1) PE20010704A1 (de)
WO (1) WO2001024822A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
WO2006033665A1 (en) 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
EP1619207A3 (de) * 2000-09-01 2006-02-08 Epimmune Inc. HLA-A2.1- Bindungspeptide stammend von HCV und ihre Verwendung
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
CA2433967A1 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1390494A2 (de) * 2001-05-21 2004-02-25 Intercell AG Verfahren zur stabilisierung von nukleinsäuren
EP1523557A2 (de) 2002-07-24 2005-04-20 Intercell AG Bei alternativen leserahmen kodiertete antigenen aus pathogenischen viren
EP2402026A3 (de) 2002-09-13 2012-04-18 Intercell AG Verfahren zum Isolieren von Hepatitis-C-Virus-Peptiden
AU2003274011B2 (en) 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
AU2003303646B2 (en) 2002-12-31 2010-03-04 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
DK1601770T3 (da) 2003-03-04 2009-11-02 Intercell Ag Streptococcus pyogenes antigener
WO2004084938A1 (en) 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
EP2311989A1 (de) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae Antigene
JP2007535894A (ja) 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・アガラクティエ抗原ｉ＋ｉｉ
CN102304527A (zh) 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
PL1648502T3 (pl) * 2003-07-11 2011-05-31 Intercell Ag Szczepionki przeciwko HCV
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US20080145383A1 (en) * 2004-03-12 2008-06-19 Intercell Ag Method for Solubilizing Peptide Mixtures
EP1791858B1 (de) 2004-09-24 2010-04-21 Intercell AG Verändertes vp-1capsidprotein von parvovirus b19
DE602005015605D1 (de) * 2004-10-29 2009-09-03 Intercell Ag Hcv impfstoff für chronische hcv patienten
CA2634053A1 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US20090186047A1 (en) * 2006-04-25 2009-07-23 Intercell Ag HCV Vaccinations
EP2287189A1 (de) 2006-07-07 2011-02-23 Intercell AG Kleine Streptococcus pyogenes Antigene und die Verwendung davon
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
EP2266592A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2167530A2 (de) 2007-06-18 2010-03-31 Intercell AG Chlamydia-antigene
WO2009046872A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US8241643B2 (en) 2008-03-17 2012-08-14 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
WO2009129498A2 (en) * 2008-04-17 2009-10-22 Immuneregen Biosciences, Inc. Substance p and analogs thereof as a cancer immunogenic composition adjuvant
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
CA2755897C (en) 2009-03-23 2020-01-28 Nanirx, Inc. Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
US8321012B2 (en) 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
EP2753352B2 (de) 2010-09-03 2022-08-10 Valneva Austria GmbH Isoliertes polypeptid der toxin a und toxin b aus c. difficile und verwendung davon
EP2446898A1 (de) * 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
CN103747798B (zh) * 2011-05-18 2018-10-26 马特里瓦克斯公司 包含聚阳离子的蛋白质基质疫苗组合物
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
US10398772B2 (en) 2014-01-08 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
US10816554B2 (en) 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
AU2020277661A1 (en) 2019-05-20 2021-10-21 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
EP3980056A4 (de) 2019-05-31 2023-03-29 Universidad De Chile Immunogene formulierung, die einen schutz gegen shiga-toxin-produzierende escherichia coli (stec) induziert
CN117279659A (zh) 2021-04-09 2023-12-22 瓦尔尼瓦公司 人偏肺病毒疫苗
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (de) * 1968-05-31 1972-09-20
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
AU6073386A (en) 1985-07-30 1987-02-05 International Minerals & Chemical Corporation Stabilization of growth promoting hormones
US4837202A (en) 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8821656D0 (en) 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
FR2658895B1 (fr) 1990-02-27 1992-07-03 Hydraulique Meca Ste Nle Gle Robinet-vanne.
GB9010058D0 (en) * 1990-05-04 1990-06-27 Health Lab Service Board Method and composition for the treatment of cancer
US6172189B1 (en) * 1990-08-24 2001-01-09 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
JPH06199894A (ja) * 1992-08-27 1994-07-19 Asahi Chem Ind Co Ltd Ｃ型肝炎ウイルスのコア蛋白質領域に存在するｔ細胞エピトープ
EP0587958A1 (de) 1992-09-14 1994-03-23 Fabriques De Tabac Reunies S.A. Verfahren und vorrichtung zur Regulierung der Geschwindigkeit eines Produktes in einer Leitung und Zigarettenherstellungsmaschine mit einer solchen Vorrichtung
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
FR2708855B1 (fr) * 1993-08-13 1995-10-13 Dolisos Lab Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
EP0979867A3 (de) * 1993-11-04 2007-06-13 Innogenetics N.V. Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
JPH10503473A (ja) * 1994-04-08 1998-03-31 アメリカ合衆国 細胞傷害性ｔリンパ球刺激およびｈｃｖ曝露診断用ｃ型肝炎ウイルスコアペプチド
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
AU7008896A (en) * 1995-08-21 1997-03-12 Duke University A method to increase the density of antigen on antigen presenting cells
DK1568772T3 (da) 1995-09-21 2010-10-18 Genentech Inc Varianter af humant væksthormon
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
DE69836543T2 (de) * 1997-05-01 2007-09-20 Protechtion Unlimited, Inc., Wilmington Nervenwachstumsfaktor als impfstoffadjuvans
NZ502168A (en) * 1997-07-10 2002-08-28 Ctl Immunotherapies Corp Inducing and maintaining a CTL response by delivering antigen to the lymphatic system of a mammal via an external apparatus
AUPP060097A0 (en) 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response
US6072889A (en) 1997-12-03 2000-06-06 The Raytheon Company Method and system for imaging target detection
EP1105496B1 (de) * 1998-08-21 2007-03-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifizierte hcv peptid-impfstoffe
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
PL1648502T3 (pl) 2003-07-11 2011-05-31 Intercell Ag Szczepionki przeciwko HCV
DE602005015605D1 (de) * 2004-10-29 2009-09-03 Intercell Ag Hcv impfstoff für chronische hcv patienten

Also Published As

Publication number Publication date
US20090104217A1 (en) 2009-04-23
EP1218031B1 (de) 2006-06-28
EP1218031A2 (de) 2002-07-03
WO2001024822A2 (en) 2001-04-12
PE20010704A1 (es) 2001-07-11
AU7912100A (en) 2001-05-10
AT408721B (de) 2002-02-25
US20110300169A1 (en) 2011-12-08
EP2269640A3 (de) 2011-05-04
EP2269640A2 (de) 2011-01-05
DE60029115D1 (de) 2006-08-10
US20030099663A1 (en) 2003-05-29
EP2269641A3 (de) 2011-05-04
DE60029115T2 (de) 2007-06-14
AR025937A1 (es) 2002-12-18
EP2269642A3 (de) 2011-05-04
EP1745798A3 (de) 2007-03-07
EP1745798A2 (de) 2007-01-24
US20050163797A1 (en) 2005-07-28
WO2001024822A3 (en) 2001-12-20
EP2269643A2 (de) 2011-01-05
EP2269643A3 (de) 2011-05-04
EP2269642A2 (de) 2011-01-05
US8277815B2 (en) 2012-10-02
EP2269641A2 (de) 2011-01-05
ATE331529T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
ATA168099A (de) Pharmazeutische zusammensetzung enthaltend ein antigen
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE60142197D1 (de) Pharmazeutische Zusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
NO20015175L (no) Farmasöytisk sammensetning
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
ATE238812T1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
DE69904312D1 (de) Pharmazeutische aerosolformulierung
ATE230611T1 (de) Pharmazeutische zusammensetzungen mit plasmaproteinen
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
DE59915033D1 (de) Pharmazeutische Zubereitung
DE60315939D1 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
DZ3219A1 (fr) Vaccin
DE59910298D1 (de) Pharmazeutische levothyroxinzubereitung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
AR025867A1 (es) Formulacion portasdora farmaceutica
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: INTERCELL AG, AT

Effective date: 20120919

MM01 Lapse because of not paying annual fees

Effective date: 20130715